未登录

D

David Lu

Stanford University

H指数:13

被引数:1,705

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Detection and characterization of in cellulo protein–RNA complexity by irCLIP-RNP, irCLIPv2 and Re-CLIP

通过irCLIP-RNP、irCLIPv2和Re-CLIP检测和表征细胞内蛋白质-RNA复合物的复杂性

Nature Protocols

IF16

2026-11-060

PRE

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

NATURE COMMUNICATIONS

IF15.7

2022-11-1014

OAAI

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

CLINICAL CANCER RESEARCH

IF10.2

2019-11-0143

OAAI

Single-cell analyses reveal increasing intratumoral heterogeneity as an essential component of treatment resistance in small cell lung cancer

CANCER RESEARCH

IF16.6

2019-07-010

PRE

SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer

CANCER RESEARCH

IF16.6

2019-07-014

PRE

Simultaneous characterization and quantification of immune cell subpopulations and PD-L1 expressing CTCs in peripheral blood of cancer patients

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer

CANCER RESEARCH

IF16.6

2017-10-15106

OAAI

Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

IF3.4

2017-07-0468

OAAI

Quantification of rare PD-L1 expressing leukocytes and CTCs in peripheral blood of cancer patients

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer

EUROPEAN UROLOGY

IF25.2

2017-06-01131

OAAI

Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)

ANNALS OF ONCOLOGY

IF65.4

2016-10-011

OAAI

PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naive lung cancer in a prospective, multicenter study

ANNALS OF ONCOLOGY

IF65.4

2016-10-010

OAAI

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

IF3.4

2016-09-2298

OAAI

Nuclear localized AR-V7 protein as a predictive biomarker for treatment selection in metastatic castration resistant prostate cancer (mCRPC)

CANCER RESEARCH

IF16.6

2016-07-150

PRE

Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx)

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-09-010

PREAI

Single cell analysis of AR N terminal, AR C terminal and the ARv7 splice variant in the CTCs of metastatic castration resistant prostate cancer (mCRPC) patients

CANCER RESEARCH

IF16.6

2015-08-011

PRE

Recovery and characterization of circulating tumor cells (CTCs) in cryopreserved metastatic castrate-resistant prostate cancer (mCRPC) patient samples

CANCER RESEARCH

IF16.6

2015-08-010

PRE

Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells

IF10.1

2015-03-0181

OAAI

Characterization of ALK fusions in circulating tumor cells (CTCs) of NSCLC

CANCER RESEARCH

IF16.6

2014-10-011

PRE

Identification of a Natural Compound by Cell-Based Screening That Enhances Interferon Regulatory Factor-1 Activity and Causes Tumor Suppression

MOLECULAR CANCER THERAPEUTICS

IF5.5

2011-10-0912

OAAI